Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18.
Many RNA viruses are displaying great promise in the field of oncolytic virotherapy. Previously, we reported that the picornavirus Coxsackievirus A21 (CVA21) possessed potent oncolytic activity against cultured malignant melanoma cells and melanoma xenografts in mice. In the present study, we demonstrate that three additional Group A Coxsackieviruses; Coxsackievirus A13 (CVA13), Coxsackievirus A15 (CVA15) and Coxsackievirus A18 (CVA18), also have similar oncolytic activity against malignant melanoma. Each of the viruses grew quickly to high titers in cancer cells expressing ICAM-1 and intratumoral injection of preformed subcutaneous SK-Mel-28 xenografts in mice with CVA13, CVA15 and CVA18 resulted in significant tumor volume reduction.As preexisting immunity could potentially hinder oncolytic virotherapy, sera from stage IV melanoma patients and normal controls were tested for levels of protective antibody against the panel of oncolytic Coxsackieviruses. Serum neutralization assays revealed that 3 of 21 subjects possessed low levels of anti-CVA21 antibodies, while protective antibodies for CVA13, CVA15 and CVA18 were not detected in any sample. Serum from individuals who were seropositive for CVA21 failed to exhibit cross-neutralization of CVA13, CVA15 and CVA18. From these studies it can be concluded that the administration of CVA13, CVA15 or CVA18 could be employed as a potential multivalent oncolytic therapy against malignant melanoma.
The Picornaviral Research Unit, The School of Biomedical Sciences and Pharmacy, Faculty of Health, The University of Newcastle, Newcastle, New South Wales 2300, Australia. gough.au@newcastle.edu.au
Gough G
GG
Au
Leone G
LG
Beagley
Erin S
ES
Haley
Richard D
RD
Barry
Darren R
DR
Shafren
D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D029821:Enterovirus A, Human / Q000254:growth & development*; D006801:Humans; D008545:Melanoma / Q000473:pathology / Q000628:therapy* / Q000821:virology*; D051379:Mice; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000254:growth & development*; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy / Q000821:virology; D014183:Transplantation, Heterologous / Q000473:pathology; D016896:Treatment Outcome; D019562:Viral Load
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral
Cancer Metastasis Rev. 1999;18(3):345-57
10721489
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):53-60
14734451
Ann Plast Surg. 2010 Feb;64(2):132-3
20098088
Immunobiology. 1988 Dec;178(3):275-84
3229781
Transfusion. 2003 Aug;43(8):1060-6
12869111
J Mol Med (Berl). 1996 Jan;74(1):13-33
8834767
J Gen Virol. 2003 Nov;84(Pt 11):3041-3050
14573809
Proc Natl Acad Sci U S A. 1989 Jan;86(2):641-4
2643120
Arch Dermatol Res. 2005 Dec;297(6):256-60
16222535
Am J Hyg. 1958 Nov;68(3):272-87
13594929
J Virol. 1997 Jun;71(6):4736-43
9151867
Int J Oncol. 2005 Jun;26(6):1471-6
15870858
Cancer Res. 2008 Dec 1;68(23):9854-64
19047166